<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00907777</url>
  </required_header>
  <id_info>
    <org_study_id>112807</org_study_id>
    <nct_id>NCT00907777</nct_id>
  </id_info>
  <brief_title>Vaccination With GSK 1024850A in Children Primed With GSK 1024850A &amp; Boosted With Pneumovax 23™</brief_title>
  <official_title>Vaccination With the Pneumococcal Vaccine GSK 1024850A or Prevenar™ at Approximately 4 Years of Age in Children Primed With 3 Doses of GSK 1024850A Vaccine or Prevenar™ and Boosted With 23-valent Pneumococcal Plain Polysaccharide Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the immune response, safety and reactogenicity following
      administration of an additional dose of a pneumococcal conjugate vaccine at approximately 4
      years of age in children previously vaccinated with 3 primary doses of GSK 1024850A or
      Prevenar™ vaccine within the first 6 months of life and a booster dose of plain
      polysaccharide pneumococcal (Pneumovax 23™) vaccine at 11-14 months of age.

      Antibody persistence will also be assessed at approximately 4 years of age in children
      previously vaccinated with 3 doses of either GSK 1024850A or Prevenar™ vaccine followed by a
      booster dose of Pneumovax 23™.

      This protocol posting deals with objectives &amp; outcome measures of the extension phase at year
      4. The objectives &amp; outcome measures of the primary phase are presented in a separate
      protocol posting (NCT 00307541). The objectives &amp; outcome measures of the booster phase are
      presented in a separate protocol posting (NCT 00333450).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vaccine Pneumococcal Serotype Antibody Concentrations</measure>
    <time_frame>Before (PRE) and one month after (POST) the additional dose</time_frame>
    <description>The anti-pneumococcal antibody concentration cut-off value assessed was greater than or equal to ≥ 0.05 microgram per milliliter (μg/mL). The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes</measure>
    <time_frame>Before (PRE) and one month after (POST) the additional dose</time_frame>
    <description>The opsonophagocytic activity cut-off value assessed was greater than or equal to ≥ 8. The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cross-reactive Pneumococcal Serotype Antibody Concentrations</measure>
    <time_frame>Before (PRE) and one month after (POST) the additional dose</time_frame>
    <description>The anti-pneumococcal antibody concentration cut-off value assessed was greater than or equal to ≥ 0.05 microgram per milliliter (μg/mL). The cross-reactive pneumococcal serotypes assessed include 6A and 19A.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes</measure>
    <time_frame>Before (PRE) and one month after (POST) the additional dose</time_frame>
    <description>The opsonophagocytic activity cut-off value assessed was greater than or equal to ≥ 8. The cross-reactive pneumococcal serotypes assessed include 6A and 19A.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-protein D Antibody Concentrations</measure>
    <time_frame>Before (PRE) and one month after (POST) the additional dose</time_frame>
    <description>The anti-protein D antibody cut-off value (greater than or equal to ≥100 EL.U/mL) was assessed by Enzyme-Linked Immuno Sorbent Assay (ELISA) unit per milliliter (EL.U/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms</measure>
    <time_frame>During the 8-day (Days 0-7) post-additional dose</time_frame>
    <description>Solicited general symptoms assessed include pain, redness, and swelling. Grade 3 pain was defined as crying when limb was moved/spontaneously painful. Grade 3 swelling/redness was defined as swelling/redness larger (&gt;) 30 millimeters (mm). &quot;Any&quot; is defined as incidence of the specified symptom regardless of intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms</measure>
    <time_frame>During the 8-day (Days 0-7) post-additional dose</time_frame>
    <description>Solicited general symptoms assessed include drowsiness, fever (defined as rectal temperature ≥ 38.0°C), irritability, and loss of appetite. Grade 3 drowsiness was defined as drowsiness which prevented normal everyday activities. Grade 3 fever was defined as fever (rectal temperature) above (&gt;) 40.0 degree Celsius (°C). Grade 3 irritability was defined as crying that could not be comforted/preventing normal everyday activities. Grade 3 loss of appetite was defined as the subject not eating at all. &quot;Any&quot; is defined as incidence of the specified symptom regardless of intensity or relationship to study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Unsolicited Adverse Events (AEs)</measure>
    <time_frame>Within 31 days (Day 0-30) post-additional vaccination</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. &quot;Any&quot; is defined an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Serious Adverse Events (SAEs)</measure>
    <time_frame>Throughout the entire study period (approximately 1 month per subject)</time_frame>
    <description>An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or may evolve into one of the outcomes listed above.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Infections, Streptococcal</condition>
  <arm_group>
    <arm_group_label>Pn Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receiving GSK 1024850A vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prev Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects receiving Prevenar™ vaccine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumococcal conjugate vaccine GSK 1024850A</intervention_name>
    <description>One dose of vaccine will be injected intramuscularly into the deltoid.</description>
    <arm_group_label>Pn Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumococcal conjugate vaccine Prevenar™ (Wyeth Lederle's)</intervention_name>
    <description>One dose of vaccine will be injected intramuscularly into the deltoid.</description>
    <arm_group_label>Prev Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female between, and including, 46-50 months of age at the time of vaccination.

          -  Subjects for whom the investigator believes that their parents/guardians can and will
             comply with the requirements of the protocol.

          -  Subjects who previously participated in study NCT00333450 in centres with more than 2
             subjects and received a booster dose of Pneumovax 23™.

          -  Written informed consent obtained from both parents/guardians of the subject.

          -  Healthy subjects as established by medical history and clinical examination before
             entering into the study.

        Exclusion Criteria:

          -  Use of any investigational or non-registered product other than the study vaccine(s)
             within 30 days preceding the vaccination, or planned use during the study period.

          -  Chronic administration of immunosuppressants or other immune-modifying drugs within
             six months prior to the vaccination.

          -  Planned administration/ administration of a vaccine not foreseen by the study protocol
             during the period starting one month before study vaccination and during the entire
             study period.

          -  Administration of any pneumococcal vaccine since the end of study NCT00333450.

          -  Administration of immunoglobulins and/or any blood products less than 3 months prior
             to the vaccination or planned use during the study period.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical

          -  History of any neurologic disorders or seizures

          -  Anaphylactic reaction following previous administration of the vaccine or history of
             reactions or allergic disease likely to be exacerbated by any component of the
             vaccine.

          -  History of hypotonic-hyporesponsive episode after any previous vaccination.

          -  Major congenital defects or serious chronic illness.

          -  History of invasive pneumococcal diseases.

          -  Acute disease at the time of vaccination

          -  Rectal temperature &gt;= 38.0°C or oral/axillary/tympanic temperature &gt;= 37.5°C. A
             temperature greater than or equal to these cut-offs warrants deferral of the
             vaccination pending recovery of the subject.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>46 Months</minimum_age>
    <maximum_age>50 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Wuerttemberg</state>
        <zip>68163</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marbach</city>
        <state>Baden-Wuerttemberg</state>
        <zip>71672</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Noerdlingen</city>
        <state>Bayern</state>
        <zip>86720</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bad Oeynhausen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>32549</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Goch</city>
        <state>Nordrhein-Westfalen</state>
        <zip>47574</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Heiligenhaus</city>
        <state>Nordrhein-Westfalen</state>
        <zip>42579</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moenchengladbach</city>
        <state>Nordrhein-Westfalen</state>
        <zip>41061</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moenchengladbach</city>
        <state>Nordrhein-Westfalen</state>
        <zip>41236</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Willich</city>
        <state>Nordrhein-Westfalen</state>
        <zip>47877</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Frankenthal</city>
        <state>Rheinland-Pfalz</state>
        <zip>67227</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04178</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lobenstein</city>
        <state>Thueringen</state>
        <zip>07356</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Neuhaus am Rennweg</city>
        <state>Thueringen</state>
        <zip>98724</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Weimar</city>
        <state>Thueringen</state>
        <zip>99425</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10315</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>14197</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Knuf M, Pankow-Culot H, Grunert D, Rapp M, Panzer F, Köllges R, Fanic A, Habib A, Borys D, Dieussaert I, Schuerman L. Induction of immunologic memory following primary vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in infants. Pediatr Infect Dis J. 2012 Jan;31(1):e31-6. doi: 10.1097/INF.0b013e3182323ac2.</citation>
    <PMID>21909049</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2009</study_first_submitted>
  <study_first_submitted_qc>May 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2009</study_first_posted>
  <results_first_submitted>November 7, 2016</results_first_submitted>
  <results_first_submitted_qc>November 7, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 6, 2017</results_first_posted>
  <disposition_first_submitted>November 10, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>November 10, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 11, 2009</disposition_first_posted>
  <last_update_submitted>November 7, 2016</last_update_submitted>
  <last_update_submitted_qc>November 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Haemophilus influenzae</keyword>
  <keyword>Streptococcus pneumoniae</keyword>
  <keyword>safety</keyword>
  <keyword>Pneumococcal conjugate vaccine</keyword>
  <keyword>immunogenicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Streptococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>112807</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112807</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112807</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112807</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112807</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112807</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>During the screening the following steps occurred: check for inclusion/exclusion criteria, contraindications/precautions, medical history of the subjects and signing informed consent forms.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Prevnar Group</title>
          <description>Subjects who were previously vaccinated with three primary doses of Prevnar™ vaccine in study 2005-003299-40 [10PN-PD-DIT-003 (105554)] and a booster dose of Pneumovax 23™ vaccine in study 2006-000560-93 [10PN-PD-DIT-008 BST: 003 (106623)], received one additional dose of Prevnar™ vaccine, administered intramuscularly in the deltoid, at approximately 4 years of age.</description>
        </group>
        <group group_id="P2">
          <title>GSK 1024850A Group</title>
          <description>Subjects who were previously vaccinated with three primary doses of GSK 1024850A vaccine in study 2005-003299-40 [10PN-PD-DIT-003 (105554)] and a booster dose of Pneumovax 23™ vaccine in study 2006-000560-93 [10PN-PD-DIT-008 BST: 003 (106623)], received one additional dose of GSK 1024850A vaccine, administered intramuscularly in the deltoid, at approximately 4 years of age.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Prevnar Group</title>
          <description>Subjects who were previously vaccinated with three primary doses of Prevnar™ vaccine in study 2005-003299-40 [10PN-PD-DIT-003 (105554)] and a booster dose of Pneumovax 23™ vaccine in study 2006-000560-93 [10PN-PD-DIT-008 BST: 003 (106623)], received one additional dose of Prevnar™ vaccine, administered intramuscularly in the deltoid, at approximately 4 years of age.</description>
        </group>
        <group group_id="B2">
          <title>GSK 1024850A Group</title>
          <description>Subjects who were previously vaccinated with three primary doses of GSK 1024850A vaccine in study 2005-003299-40 [10PN-PD-DIT-003 (105554)] and a booster dose of Pneumovax 23™ vaccine in study 2006-000560-93 [10PN-PD-DIT-008 BST: 003 (106623)], received one additional dose of GSK 1024850A vaccine, administered intramuscularly in the deltoid, at approximately 4 years of age.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="52"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.6" spread="0.91"/>
                    <measurement group_id="B2" value="46.7" spread="0.72"/>
                    <measurement group_id="B3" value="46.65" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Vaccine Pneumococcal Serotype Antibody Concentrations</title>
        <description>The anti-pneumococcal antibody concentration cut-off value assessed was greater than or equal to ≥ 0.05 microgram per milliliter (μg/mL). The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.</description>
        <time_frame>Before (PRE) and one month after (POST) the additional dose</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom data concerning immunogenicity endpoint measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Prevnar Group</title>
            <description>Subjects who were previously vaccinated with three primary doses of Prevnar™ vaccine in study 2005-003299-40 [10PN-PD-DIT-003 (105554)] and a booster dose of Pneumovax 23™ vaccine in study 2006-000560-93 [10PN-PD-DIT-008 BST: 003 (106623)], received one additional dose of Prevnar™ vaccine, administered intramuscularly in the deltoid, at approximately 4 years of age.</description>
          </group>
          <group group_id="O2">
            <title>GSK 1024850A Group</title>
            <description>Subjects who were previously vaccinated with three primary doses of GSK 1024850A vaccine in study 2005-003299-40 [10PN-PD-DIT-003 (105554)] and a booster dose of Pneumovax 23™ vaccine in study 2006-000560-93 [10PN-PD-DIT-008 BST: 003 (106623)], received one additional dose of GSK 1024850A vaccine, administered intramuscularly in the deltoid, at approximately 4 years of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Vaccine Pneumococcal Serotype Antibody Concentrations</title>
          <description>The anti-pneumococcal antibody concentration cut-off value assessed was greater than or equal to ≥ 0.05 microgram per milliliter (μg/mL). The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom data concerning immunogenicity endpoint measures were available.</population>
          <units>microgram/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ANTI-1 PRE (N=21,24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" lower_limit="0.09" upper_limit="0.23"/>
                    <measurement group_id="O2" value="0.38" lower_limit="0.25" upper_limit="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-1 POST (N=24,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" lower_limit="0.1" upper_limit="0.25"/>
                    <measurement group_id="O2" value="1.35" lower_limit="1.05" upper_limit="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-4 PRE (N=21,24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" lower_limit="0.15" upper_limit="0.5"/>
                    <measurement group_id="O2" value="0.12" lower_limit="0.08" upper_limit="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-4 POST (N=24,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" lower_limit="3.38" upper_limit="5.48"/>
                    <measurement group_id="O2" value="6.76" lower_limit="4.91" upper_limit="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-5 PRE (N=21,24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" lower_limit="0.08" upper_limit="0.16"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.34" upper_limit="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-5 POST (N=24,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" lower_limit="0.1" upper_limit="0.22"/>
                    <measurement group_id="O2" value="1.78" lower_limit="1.34" upper_limit="2.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-6B PRE (N=21,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" lower_limit="0.38" upper_limit="1.12"/>
                    <measurement group_id="O2" value="0.48" lower_limit="0.26" upper_limit="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-6B POST (N=24,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.46" lower_limit="4.61" upper_limit="12.08"/>
                    <measurement group_id="O2" value="1.68" lower_limit="1.1" upper_limit="2.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-7F PRE (N=21,24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" lower_limit="0.1" upper_limit="0.32"/>
                    <measurement group_id="O2" value="0.39" lower_limit="0.26" upper_limit="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-7F POST (N=24,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" lower_limit="0.11" upper_limit="0.32"/>
                    <measurement group_id="O2" value="2.53" lower_limit="1.83" upper_limit="3.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-9V PRE (N=21,24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" lower_limit="0.27" upper_limit="0.86"/>
                    <measurement group_id="O2" value="0.44" lower_limit="0.29" upper_limit="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-9V POST (N=24,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.88" lower_limit="4.98" upper_limit="9.51"/>
                    <measurement group_id="O2" value="2.13" lower_limit="1.54" upper_limit="2.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-14 PRE (N=21,24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="0.82" upper_limit="2.74"/>
                    <measurement group_id="O2" value="1.98" lower_limit="1.14" upper_limit="3.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-14 POST (N=24,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.82" lower_limit="14.65" upper_limit="45.5"/>
                    <measurement group_id="O2" value="9.71" lower_limit="5.61" upper_limit="16.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-18C PRE (N=21,24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34" lower_limit="0.2" upper_limit="0.58"/>
                    <measurement group_id="O2" value="0.48" lower_limit="0.26" upper_limit="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-18C POST (N=24,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.23" lower_limit="2.94" upper_limit="6.08"/>
                    <measurement group_id="O2" value="6.4" lower_limit="4.61" upper_limit="8.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-19F PRE (N=21,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.02" lower_limit="1.29" upper_limit="3.16"/>
                    <measurement group_id="O2" value="2.37" lower_limit="1.41" upper_limit="3.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-19F POST (N=24,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.68" lower_limit="3.82" upper_limit="8.45"/>
                    <measurement group_id="O2" value="15.61" lower_limit="11.51" upper_limit="21.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-23F PRE (N=21,24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" lower_limit="0.2" upper_limit="0.53"/>
                    <measurement group_id="O2" value="0.23" lower_limit="0.12" upper_limit="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-23F POST (N=24,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.82" lower_limit="3.77" upper_limit="8.97"/>
                    <measurement group_id="O2" value="1.27" lower_limit="0.9" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes</title>
        <description>The opsonophagocytic activity cut-off value assessed was greater than or equal to ≥ 8. The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.</description>
        <time_frame>Before (PRE) and one month after (POST) the additional dose</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom data concerning immunogenicity endpoint measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Prevnar Group</title>
            <description>Subjects who were previously vaccinated with three primary doses of Prevnar™ vaccine in study 2005-003299-40 [10PN-PD-DIT-003 (105554)] and a booster dose of Pneumovax 23™ vaccine in study 2006-000560-93 [10PN-PD-DIT-008 BST: 003 (106623)], received one additional dose of Prevnar™ vaccine, administered intramuscularly in the deltoid, at approximately 4 years of age.</description>
          </group>
          <group group_id="O2">
            <title>GSK 1024850A Group</title>
            <description>Subjects who were previously vaccinated with three primary doses of GSK 1024850A vaccine in study 2005-003299-40 [10PN-PD-DIT-003 (105554)] and a booster dose of Pneumovax 23™ vaccine in study 2006-000560-93 [10PN-PD-DIT-008 BST: 003 (106623)], received one additional dose of GSK 1024850A vaccine, administered intramuscularly in the deltoid, at approximately 4 years of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes</title>
          <description>The opsonophagocytic activity cut-off value assessed was greater than or equal to ≥ 8. The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom data concerning immunogenicity endpoint measures were available.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>OPSONO-1 PRE (N=22,25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="5.8" lower_limit="3.6" upper_limit="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-1 POST (N=24,25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" lower_limit="3.4" upper_limit="9.1"/>
                    <measurement group_id="O2" value="49.3" lower_limit="25.5" upper_limit="95.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-4 PRE (N=21,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.7" lower_limit="6.4" upper_limit="67.5"/>
                    <measurement group_id="O2" value="12.3" lower_limit="4.5" upper_limit="33.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-4 POST (N=24,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4814" lower_limit="3380.8" upper_limit="6854.6"/>
                    <measurement group_id="O2" value="4380.7" lower_limit="3020.5" upper_limit="6353.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-5 PRE (N=23,25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="3.8" upper_limit="4.6"/>
                    <measurement group_id="O2" value="7.5" lower_limit="4.5" upper_limit="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-5 POST (N=24,25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" lower_limit="3.8" upper_limit="5.1"/>
                    <measurement group_id="O2" value="50.6" lower_limit="30.8" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-6B PRE (N=22,24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188.2" lower_limit="55.5" upper_limit="638"/>
                    <measurement group_id="O2" value="66.3" lower_limit="19.7" upper_limit="222.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-6B POST (N=24,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6734.3" lower_limit="3873.2" upper_limit="11708.7"/>
                    <measurement group_id="O2" value="1424.5" lower_limit="775" upper_limit="2618.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-7F PRE (N=22,24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1202.9" lower_limit="809" upper_limit="1788.8"/>
                    <measurement group_id="O2" value="1498.9" lower_limit="1097.8" upper_limit="2046.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-7F POST (N=24,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1304.2" lower_limit="880.7" upper_limit="1931.4"/>
                    <measurement group_id="O2" value="4657.1" lower_limit="3321.2" upper_limit="6530.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-9V PRE (N=22,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="612.9" lower_limit="458.6" upper_limit="819.3"/>
                    <measurement group_id="O2" value="442" lower_limit="224.5" upper_limit="870.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-9V POST (N=23,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5829.4" lower_limit="3909.1" upper_limit="8693.2"/>
                    <measurement group_id="O2" value="2843.5" lower_limit="2016" upper_limit="4010.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-14 PRE (N=21,25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149.7" lower_limit="65.2" upper_limit="343.5"/>
                    <measurement group_id="O2" value="330" lower_limit="186.5" upper_limit="584"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-14 POST (N=24,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5400.8" lower_limit="3491.3" upper_limit="8354.8"/>
                    <measurement group_id="O2" value="2812.4" lower_limit="1734.3" upper_limit="4560.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-18C PRE (N=21,24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1" lower_limit="5.3" upper_limit="49.2"/>
                    <measurement group_id="O2" value="23.7" lower_limit="7.5" upper_limit="74.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-18C POST (N=24,25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1615.2" lower_limit="782" upper_limit="3336.1"/>
                    <measurement group_id="O2" value="2806.6" lower_limit="1408.8" upper_limit="5591.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-19F PRE (N=22,25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.1" lower_limit="14.8" upper_limit="46.1"/>
                    <measurement group_id="O2" value="35.8" lower_limit="18.6" upper_limit="68.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-19F POST (N=24,25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="241.6" lower_limit="133.6" upper_limit="436.7"/>
                    <measurement group_id="O2" value="837.3" lower_limit="559.5" upper_limit="1253.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-23F PRE (N=21,25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1430.2" lower_limit="542.5" upper_limit="3770.6"/>
                    <measurement group_id="O2" value="1383.2" lower_limit="630.2" upper_limit="3036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-23F POST (N=24,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23977.2" lower_limit="14185.3" upper_limit="40528.2"/>
                    <measurement group_id="O2" value="4865.1" lower_limit="3977" upper_limit="5951.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cross-reactive Pneumococcal Serotype Antibody Concentrations</title>
        <description>The anti-pneumococcal antibody concentration cut-off value assessed was greater than or equal to ≥ 0.05 microgram per milliliter (μg/mL). The cross-reactive pneumococcal serotypes assessed include 6A and 19A.</description>
        <time_frame>Before (PRE) and one month after (POST) the additional dose</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom data concerning immunogenicity endpoint measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Prevnar Group</title>
            <description>Subjects who were previously vaccinated with three primary doses of Prevnar™ vaccine in study 2005-003299-40 [10PN-PD-DIT-003 (105554)] and a booster dose of Pneumovax 23™ vaccine in study 2006-000560-93 [10PN-PD-DIT-008 BST: 003 (106623)], received one additional dose of Prevnar™ vaccine, administered intramuscularly in the deltoid, at approximately 4 years of age.</description>
          </group>
          <group group_id="O2">
            <title>GSK 1024850A Group</title>
            <description>Subjects who were previously vaccinated with three primary doses of GSK 1024850A vaccine in study 2005-003299-40 [10PN-PD-DIT-003 (105554)] and a booster dose of Pneumovax 23™ vaccine in study 2006-000560-93 [10PN-PD-DIT-008 BST: 003 (106623)], received one additional dose of GSK 1024850A vaccine, administered intramuscularly in the deltoid, at approximately 4 years of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Cross-reactive Pneumococcal Serotype Antibody Concentrations</title>
          <description>The anti-pneumococcal antibody concentration cut-off value assessed was greater than or equal to ≥ 0.05 microgram per milliliter (μg/mL). The cross-reactive pneumococcal serotypes assessed include 6A and 19A.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom data concerning immunogenicity endpoint measures were available.</population>
          <units>microgram/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ANTI-6A PRE (N=21,24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" lower_limit="0.13" upper_limit="0.37"/>
                    <measurement group_id="O2" value="0.19" lower_limit="0.12" upper_limit="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-6A POST (N=24,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.78" lower_limit="0.88" upper_limit="3.59"/>
                    <measurement group_id="O2" value="0.47" lower_limit="0.29" upper_limit="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-19A PRE (N=21,24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" lower_limit="0.2" upper_limit="0.78"/>
                    <measurement group_id="O2" value="0.29" lower_limit="0.17" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-19A POST (N=24,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0.44" upper_limit="1.44"/>
                    <measurement group_id="O2" value="1.24" lower_limit="0.79" upper_limit="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes</title>
        <description>The opsonophagocytic activity cut-off value assessed was greater than or equal to ≥ 8. The cross-reactive pneumococcal serotypes assessed include 6A and 19A.</description>
        <time_frame>Before (PRE) and one month after (POST) the additional dose</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom data concerning immunogenicity endpoint measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Prevnar Group</title>
            <description>Subjects who were previously vaccinated with three primary doses of Prevnar™ vaccine in study 2005-003299-40 [10PN-PD-DIT-003 (105554)] and a booster dose of Pneumovax 23™ vaccine in study 2006-000560-93 [10PN-PD-DIT-008 BST: 003 (106623)], received one additional dose of Prevnar™ vaccine, administered intramuscularly in the deltoid, at approximately 4 years of age.</description>
          </group>
          <group group_id="O2">
            <title>GSK 1024850A Group</title>
            <description>Subjects who were previously vaccinated with three primary doses of GSK 1024850A vaccine in study 2005-003299-40 [10PN-PD-DIT-003 (105554)] and a booster dose of Pneumovax 23™ vaccine in study 2006-000560-93 [10PN-PD-DIT-008 BST: 003 (106623)], received one additional dose of GSK 1024850A vaccine, administered intramuscularly in the deltoid, at approximately 4 years of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes</title>
          <description>The opsonophagocytic activity cut-off value assessed was greater than or equal to ≥ 8. The cross-reactive pneumococcal serotypes assessed include 6A and 19A.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom data concerning immunogenicity endpoint measures were available.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>OPSONO-6A PRE (N=20,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106.9" lower_limit="44.7" upper_limit="255.7"/>
                    <measurement group_id="O2" value="117.7" lower_limit="43.6" upper_limit="318.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-6A POST (N=24,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2320.4" lower_limit="1180.2" upper_limit="4562.5"/>
                    <measurement group_id="O2" value="966.2" lower_limit="634.8" upper_limit="1470.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-19A PRE (N=23,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" lower_limit="4.9" upper_limit="22.1"/>
                    <measurement group_id="O2" value="19.6" lower_limit="6.6" upper_limit="58.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-19A POST (N=24,24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.3" lower_limit="42.7" upper_limit="240.7"/>
                    <measurement group_id="O2" value="153.9" lower_limit="67.7" upper_limit="349.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-protein D Antibody Concentrations</title>
        <description>The anti-protein D antibody cut-off value (greater than or equal to ≥100 EL.U/mL) was assessed by Enzyme-Linked Immuno Sorbent Assay (ELISA) unit per milliliter (EL.U/mL).</description>
        <time_frame>Before (PRE) and one month after (POST) the additional dose</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom data concerning immunogenicity endpoint measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Prevnar Group</title>
            <description>Subjects who were previously vaccinated with three primary doses of Prevnar™ vaccine in study 2005-003299-40 [10PN-PD-DIT-003 (105554)] and a booster dose of Pneumovax 23™ vaccine in study 2006-000560-93 [10PN-PD-DIT-008 BST: 003 (106623)], received one additional dose of Prevnar™ vaccine, administered intramuscularly in the deltoid, at approximately 4 years of age.</description>
          </group>
          <group group_id="O2">
            <title>GSK 1024850A Group</title>
            <description>Subjects who were previously vaccinated with three primary doses of GSK 1024850A vaccine in study 2005-003299-40 [10PN-PD-DIT-003 (105554)] and a booster dose of Pneumovax 23™ vaccine in study 2006-000560-93 [10PN-PD-DIT-008 BST: 003 (106623)], received one additional dose of GSK 1024850A vaccine, administered intramuscularly in the deltoid, at approximately 4 years of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-protein D Antibody Concentrations</title>
          <description>The anti-protein D antibody cut-off value (greater than or equal to ≥100 EL.U/mL) was assessed by Enzyme-Linked Immuno Sorbent Assay (ELISA) unit per milliliter (EL.U/mL).</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom data concerning immunogenicity endpoint measures were available.</population>
          <units>EL.U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ANTI-PD PRE (N=21,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.1" lower_limit="76.8" upper_limit="140.9"/>
                    <measurement group_id="O2" value="173.1" lower_limit="113.5" upper_limit="263.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTI-PD POST (N=24,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.9" lower_limit="64.1" upper_limit="115"/>
                    <measurement group_id="O2" value="1135.6" lower_limit="709" upper_limit="1819"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms</title>
        <description>Solicited general symptoms assessed include pain, redness, and swelling. Grade 3 pain was defined as crying when limb was moved/spontaneously painful. Grade 3 swelling/redness was defined as swelling/redness larger (&gt;) 30 millimeters (mm). &quot;Any&quot; is defined as incidence of the specified symptom regardless of intensity.</description>
        <time_frame>During the 8-day (Days 0-7) post-additional dose</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects with the additional vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Prevnar Group</title>
            <description>Subjects who were previously vaccinated with three primary doses of Prevnar™ vaccine in study 2005-003299-40 [10PN-PD-DIT-003 (105554)] and a booster dose of Pneumovax 23™ vaccine in study 2006-000560-93 [10PN-PD-DIT-008 BST: 003 (106623)], received one additional dose of Prevnar™ vaccine, administered intramuscularly in the deltoid, at approximately 4 years of age.</description>
          </group>
          <group group_id="O2">
            <title>GSK 1024850A Group</title>
            <description>Subjects who were previously vaccinated with three primary doses of GSK 1024850A vaccine in study 2005-003299-40 [10PN-PD-DIT-003 (105554)] and a booster dose of Pneumovax 23™ vaccine in study 2006-000560-93 [10PN-PD-DIT-008 BST: 003 (106623)], received one additional dose of GSK 1024850A vaccine, administered intramuscularly in the deltoid, at approximately 4 years of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms</title>
          <description>Solicited general symptoms assessed include pain, redness, and swelling. Grade 3 pain was defined as crying when limb was moved/spontaneously painful. Grade 3 swelling/redness was defined as swelling/redness larger (&gt;) 30 millimeters (mm). &quot;Any&quot; is defined as incidence of the specified symptom regardless of intensity.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects with the additional vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms</title>
        <description>Solicited general symptoms assessed include drowsiness, fever (defined as rectal temperature ≥ 38.0°C), irritability, and loss of appetite. Grade 3 drowsiness was defined as drowsiness which prevented normal everyday activities. Grade 3 fever was defined as fever (rectal temperature) above (&gt;) 40.0 degree Celsius (°C). Grade 3 irritability was defined as crying that could not be comforted/preventing normal everyday activities. Grade 3 loss of appetite was defined as the subject not eating at all. “Any” is defined as incidence of the specified symptom regardless of intensity or relationship to study vaccination.</description>
        <time_frame>During the 8-day (Days 0-7) post-additional dose</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects with the additional vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Prevnar Group</title>
            <description>Subjects who were previously vaccinated with three primary doses of Prevnar™ vaccine in study 2005-003299-40 [10PN-PD-DIT-003 (105554)] and a booster dose of Pneumovax 23™ vaccine in study 2006-000560-93 [10PN-PD-DIT-008 BST: 003 (106623)], received one additional dose of Prevnar™ vaccine, administered intramuscularly in the deltoid, at approximately 4 years of age.</description>
          </group>
          <group group_id="O2">
            <title>GSK 1024850A Group</title>
            <description>Subjects who were previously vaccinated with three primary doses of GSK 1024850A vaccine in study 2005-003299-40 [10PN-PD-DIT-003 (105554)] and a booster dose of Pneumovax 23™ vaccine in study 2006-000560-93 [10PN-PD-DIT-008 BST: 003 (106623)], received one additional dose of GSK 1024850A vaccine, administered intramuscularly in the deltoid, at approximately 4 years of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms</title>
          <description>Solicited general symptoms assessed include drowsiness, fever (defined as rectal temperature ≥ 38.0°C), irritability, and loss of appetite. Grade 3 drowsiness was defined as drowsiness which prevented normal everyday activities. Grade 3 fever was defined as fever (rectal temperature) above (&gt;) 40.0 degree Celsius (°C). Grade 3 irritability was defined as crying that could not be comforted/preventing normal everyday activities. Grade 3 loss of appetite was defined as the subject not eating at all. “Any” is defined as incidence of the specified symptom regardless of intensity or relationship to study vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects with the additional vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Unsolicited Adverse Events (AEs)</title>
        <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. “Any” is defined an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination.</description>
        <time_frame>Within 31 days (Day 0-30) post-additional vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects with the additional vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Prevnar Group</title>
            <description>Subjects who were previously vaccinated with three primary doses of Prevnar™ vaccine in study 2005-003299-40 [10PN-PD-DIT-003 (105554)] and a booster dose of Pneumovax 23™ vaccine in study 2006-000560-93 [10PN-PD-DIT-008 BST: 003 (106623)], received one additional dose of Prevnar™ vaccine, administered intramuscularly in the deltoid, at approximately 4 years of age.</description>
          </group>
          <group group_id="O2">
            <title>GSK 1024850A Group</title>
            <description>Subjects who were previously vaccinated with three primary doses of GSK 1024850A vaccine in study 2005-003299-40 [10PN-PD-DIT-003 (105554)] and a booster dose of Pneumovax 23™ vaccine in study 2006-000560-93 [10PN-PD-DIT-008 BST: 003 (106623)], received one additional dose of GSK 1024850A vaccine, administered intramuscularly in the deltoid, at approximately 4 years of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Unsolicited Adverse Events (AEs)</title>
          <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. “Any” is defined an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects with the additional vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
        <description>An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or may evolve into one of the outcomes listed above.</description>
        <time_frame>Throughout the entire study period (approximately 1 month per subject)</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects with the additional vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Prevnar Group</title>
            <description>Subjects who were previously vaccinated with three primary doses of Prevnar™ vaccine in study 2005-003299-40 [10PN-PD-DIT-003 (105554)] and a booster dose of Pneumovax 23™ vaccine in study 2006-000560-93 [10PN-PD-DIT-008 BST: 003 (106623)], received one additional dose of Prevnar™ vaccine, administered intramuscularly in the deltoid, at approximately 4 years of age.</description>
          </group>
          <group group_id="O2">
            <title>GSK 1024850A Group</title>
            <description>Subjects who were previously vaccinated with three primary doses of GSK 1024850A vaccine in study 2005-003299-40 [10PN-PD-DIT-003 (105554)] and a booster dose of Pneumovax 23™ vaccine in study 2006-000560-93 [10PN-PD-DIT-008 BST: 003 (106623)], received one additional dose of GSK 1024850A vaccine, administered intramuscularly in the deltoid, at approximately 4 years of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
          <description>An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or may evolve into one of the outcomes listed above.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects with the additional vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>SAEs: during the entire study period (approximately 1 month per subject); Solicited local and general symptoms: within 8 days after the additional vaccination; Unsolicited symptoms: within 31 days after the additional vaccination.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Prevnar Group</title>
          <description>Subjects who were previously vaccinated with three primary doses of Prevnar™ vaccine in study 2005-003299-40 [10PN-PD-DIT-003 (105554)] and a booster dose of Pneumovax 23™ vaccine in study 2006-000560-93 [10PN-PD-DIT-008 BST: 003 (106623)], received one additional dose of Prevnar™ vaccine, administered intramuscularly in the deltoid, at approximately 4 years of age.</description>
        </group>
        <group group_id="E2">
          <title>GSK 1024850A Group</title>
          <description>Subjects who were previously vaccinated with three primary doses of GSK 1024850A vaccine in study 2005-003299-40 [10PN-PD-DIT-003 (105554)] and a booster dose of Pneumovax 23™ vaccine in study 2006-000560-93 [10PN-PD-DIT-008 BST: 003 (106623)], received one additional dose of GSK 1024850A vaccine, administered intramuscularly in the deltoid, at approximately 4 years of age.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Fever (&gt;38.0°C)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Loss of appetite</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

